What's new? Log in Free sign up

Legend Biotech (LEGN)

Company Profile

Company profile

Ticker

LEGN

Exchange

Website

www.legendbiotech.com

CEO

Dr. Ying Huang Ph.D.

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Alabama Power • Mississippi Power • Teva Pharmaceutical Industries Limited • Entergy Arkansas • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb ...

Former names

TPG Pace Holdings Corp.

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

LEGN stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Redburn Atlantic

Latest filings (excl ownership)

View all

Current report (foreign)

Registration of securities for employees

Legend Biotech Reports Third Quarter 2024 Results and Recent Highlights

Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma

Current report (foreign)

Voting Results of 2024 Annual General Meeting

Current report (foreign)

Current report (foreign)

Current report (foreign)

Current report (foreign)

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

Notice of proposed sale of securities

PRICE T ROWE ASSOCIATES INC /MD/

Notice of proposed sale of securities

Notice of proposed sale of securities

Notice of proposed sale of securities

Notice of proposed sale of securities

Notice of proposed sale of securities

Notice of proposed sale of securities

Financial summary

Financial statements Chart LEGN financial data

Quarter (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Institutional ownership, Q3 2024

LEGN institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	207	181	+14.4%
Opened positions	44	29	+51.7%
Closed positions	18	46	-60.9%
Increased positions	69	81	-14.8%
Reduced positions	67	47	+42.6%

13F shares	Current	Prev Q	Change
Total value	3.87 tn	3.53 tn	+9.6%
Total shares	286.31 mm	286.88 mm	-0.2%
Total puts	349.10 k	385.50 k	-9.4%
Total calls	278.00 k	372.70 k	-25.4%
Total put/call ratio	1.3	1.0	+21.4%

Largest owners	Shares	Value	Change
GenScript Biotech	174.50 mm	$0.00	0.0%
Hillhouse Capital Management	20.27 mm	$0.00	0.0%
FMR	18.33 mm	$893.23 bn	+4.0%
T. Rowe Price	11.17 mm	$544.10 mm	-2.8%
Ra Capital Management	7.51 mm	$365.81 bn	0.0%
Hillhouse Capital Advisors	6.64 mm	$323.40 bn	0.0%
Westfield Capital Management	5.04 mm	$245.53 bn	+5.6%
BLK BlackRock	4.50 mm	$219.05 bn	NEW
IVZ Invesco	2.29 mm	$111.48 bn	+9826.3%
Massachusetts Financial Services	2.28 mm	$110.87 bn	+16.0%

Largest transactions	Shares	Bought/sold	Change
BLK BlackRock	0.00	-5.72 mm	EXIT
BLK BlackRock	4.50 mm	+4.50 mm	NEW
IVZ Invesco	2.29 mm	+2.26 mm	+9826.3%
Paradigm Biocapital Advisors	0.00	-1.20 mm	EXIT
Millennium Management	570.38 k	-1.09 mm	-65.6%
Wellington Management	2.04 mm	-773.00 k	-27.5%
FMR	18.33 mm	+708.62 k	+4.0%
Marshall Wace	494.37 k	+494.37 k	NEW
Avidity Partners Management	0.00	-398.00 k	EXIT
T. Rowe Price	11.17 mm	-323.69 k	-2.8%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

(LEGN) - Analyzing Legend Biotech's Short Interest

Deep Dive Into Legend Biotech Stock: Analyst Perspectives (10 Ratings)

HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $73 Price Target

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Legend Biotech (NASDAQ:LEGN) with a Buy and maintains $73 price target.

Reported Earlier, Legend Biotech CARVYKTI Delivers Improved MRD Negativity And Overall Survival Benefits In Phase 3 CARTITUDE-4 Study

Cantor Fitzgerald Reiterates Overweight on Legend Biotech, Maintains $83 Price Target

Press releases

From Benzinga Pro

Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SOMERSET, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company's Chief Executive

CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma

89 percent of evaluable patients achieved minimal residual disease (MRD) negativity with CARVYKTI® after three-year follow-up in CARTITUDE-4 study; the majority in less than 2 monthsResults add to the overall

Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition

SOMERSET, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ:LEGN) (Legend Biotech), a global leader in cell therapy, will host a live webcast event for investors on Sunday, December 8, 2024, at

Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma

Legend Biotech Appoints Alan Bash as President of CARVYKTI®

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.